RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI - News) announced that Meda AB, its commercialization partner for BEMA™ Fentanyl in North America and Europe, has submitted a dossier seeking approval to market BEMA™ Fentanyl for the treatment of breakthrough pain in opioid tolerant cancer patients to the German Federal Institute for Drugs and Medical Devices (BfArm). Meda has chosen to utilize the Decentralized Procedure to obtain marketing approval throughout the European Union with Germany serving as the reference member country.
